Treatment outcomes and safety of bedaquiline, delamanid, and linezolid in multidrug-resistant TB

Int J Tuberc Lung Dis. 2023 Feb 1;27(2):151-153. doi: 10.5588/ijtld.22.0466.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Humans
  • Linezolid / adverse effects
  • Treatment Outcome
  • Tuberculosis, Multidrug-Resistant* / drug therapy

Substances

  • bedaquiline
  • Linezolid
  • OPC-67683